

Boehringer loses India patent to Cipla

16 March 2015 | News | By BioSpectrum Bureau

Boehringer loses India patent to Cipla



In a landmark decision, India's patent office has revoked the patent of German-based pharmaceutical giant Boehringer Ingelheim's chronic obstructive pulmonary disease drug Spiriva (tiotropium).

Back in 2012, Boehringer received its Indian patent on Spiriva, which extended up to 2021.

In 2013, Cipla filed its patent opposition saying the drug didn't constitute invention under India's patent laws.